Androgen Receptor Survival Signaling Is Blocked by Anti-β2-microglobulin Monoclonal Antibody via a MAPK/Lipogenic Pathway in Human Prostate Cancer Cells

Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase

(2010) Dolores Di Vizio et al.   CELL CYCLE

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

(2009) L. R. Molife et al.   ANNALS OF ONCOLOGY

Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven

(2009) G. Attard et al.   CANCER RESEARCH

The Role of Androgen Receptor Mutations in Prostate Cancer Progression

(2009) G. Brooke et al.   CURRENT GENOMICS

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target

(2009) Yu Chen et al.   LANCET ONCOLOGY

Microarray coupled to quantitative RT–PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells

(2009) S Ngan et al.   ONCOGENE

Progression of prostate cancer: Multiple pathways to androgen independence

(2008) Hong-Lin Devlin et al.   CANCER LETTERS

The Prognostic Significance of Serum  2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients

(2008) A.-M. Tsimberidou et al.   CLINICAL CANCER RESEARCH

 2-Microglobulin Signaling Blockade Inhibited Androgen Receptor Axis and Caused Apoptosis in Human Prostate Cancer Cells

(2008) W.-C. Huang et al.   CLINICAL CANCER RESEARCH

Androgen receptor: role and novel therapeutic prospects in prostate cancer

(2008) Mary-Ellen Taplin   Expert Review of Anticancer Therapy